SystImmune is a biopharmaceutical company focused on developing innovative bi-specific and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for treatment of cancer. Our mission is to create biologics that directly attack the tumor and activate the immune system to enhance anti-tumor responses.
SystImmune is a US based company and a member of Biokin Pharmaceutical Co., Ltd group. We are proud to partner with Bristol Myers Squibb through a strategic collaboration and exclusive license agreement to jointly develop izalontamab brengitecan (also known as BL-B01D1, iza-bren) and with the leading venture capital firm OrbiMed. We are actively seeking additional partners interested in jointly developing and commercializing our novel therapeutics for patients worldwide.
We are a multidisciplinary team of R&D scientists, clinical experts, and biotech business professionals dedicated to developing world-class antibody-based therapies. By leveraging advanced technology platforms and maintaining a strong presence in both the U.S. and China, we enable rapid, cost-efficient clinical development with the goal of delivering transformative treatments to patients worldwide.
Incorporation of binding domains into proprietary multi-specific antibody and ADC platforms, optimization of antibody properties such as humanness, stability, and binding and generation of high-quality antigen for a tailored antibody response.
Identification of monoclonal antibodies from rabbit and alpaca using B cell enrichment and sorting, or yeast display strategies enable selection of core assets with unique characteristics defined by screening using novel miniaturized immuno-assays.
Integrated and efficient titer optimizing CHO production platforms provide the foundation of our Downstream, Upstream, Formulation, and Analytical Group capability to manufacture our biotherapeutics.
SystImmune is advancing an ambitious R&D pipeline, with active discovery efforts based in Redmond, WA and clinical development operations in Princeton, NJ. As we strengthen our capabilities and scale up the organization, we remain steadfast in our commitment to delivering the next generation of breakthrough cancer therapies to patients worldwide.
Dr. Yi Zhu
Founder and Chairman
Dr. Jie D'Elia
CEO
